Literature DB >> 10197596

Role of TCL1 and ALL1 in human leukemias and development.

C M Croce1.   

Abstract

We have investigated the role of chromosomal translocations in the pathogenesis of human leukemias. The study of T-cell chronic lymphocytic leukemias and T-cell prolymphocytic leukemia has led to the identification of TCL1, a novel gene that is deregulated by translocations, t(14;14)(q11;q32), or inversions, inv(14)(q11;q32.1). Introduction of a human TCL1 gene juxtaposed to the Ick promoter into fertilized mouse eggs resulted in the development of transgenic mice that developed mature T-cell leukemias, indicating that TCL1 is a transforming oncogene. We have also investigated acute leukemias with abnormalities at chromosome 11q23. We have identified a gene, ALL1, that can fuse to many different genes in acute leukemias. We have also shown that ALL1 can fuse with ALL1 in acute myelogenous leukemia. We have proposed that the ALL1 fusion genes may act by a dominant negative mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10197596

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Pitx2a expression alters actin-myosin cytoskeleton and migration of HeLa cells through Rho GTPase signaling.

Authors:  Qize Wei; Robert S Adelstein
Journal:  Mol Biol Cell       Date:  2002-02       Impact factor: 4.138

2.  Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis.

Authors:  E K Goldberg; J M Glendening; Z Karanjawala; A Sridhar; G J Walker; N K Hayward; A J Rice; D Kurera; Y Tebha; J W Fountain
Journal:  Am J Hum Genet       Date:  2000-07-29       Impact factor: 11.025

3.  Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated P53 degradation in HeLa cells.

Authors:  Qize Wei
Journal:  J Biol Chem       Date:  2005-08-29       Impact factor: 5.157

Review 4.  Alterations of common chromosome fragile sites in hematopoietic malignancies.

Authors:  Hideshi Ishii; Yusuke Furukawa
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

5.  Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma.

Authors:  Enrico Munari; Marianna Rinaldi; Achille Ambrosetti; Massimiliano Bonifacio; Angela Bonalumi; Marco Chilosi; Alberto Zamò
Journal:  Virchows Arch       Date:  2012-10-14       Impact factor: 4.064

6.  RPS2: a novel therapeutic target in prostate cancer.

Authors:  Min Wang; Youji Hu; Mark E Stearns
Journal:  J Exp Clin Cancer Res       Date:  2009-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.